ArticleJournal of immunological methods2007
Prediction of supertype-specific HLA class I binding peptides using support vector machines.
Article in Journal of immunological methods, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- IConMHC: a deep learning convolutional neural network model to predict peptide and MHC-I binding affinity.Immunogenetics · 2020Article
- MULTiPly: a novel multi-layer predictor for discovering general and specific types of promoters.Bioinformatics (Oxford, England) · 2019Article
- Machine Learning Methods for Predicting HLA-Peptide Binding Activity.Bioinformatics and biology insights · 2015Review
- Therapeutic Vaccine Strategies against Human Papillomavirus.Vaccines · 2014Review
- Big data analytics in immunology: a knowledge-based approach.BioMed research international · 2014Article
- Article
- MULTIPRED2: a computational system for large-scale identification of peptides predicted to bind to HLA supertypes and alleles.Journal of immunological methods · 2011Article
- Machine learning study for the prediction of transdermal peptide.Journal of computer-aided molecular design · 2011Article
- Major histocompatibility complex class I binding predictions as a tool in epitope discovery.Immunology · 2010Review
- Evaluation of MHC-II peptide binding prediction servers: applications for vaccine research.BMC bioinformatics · 2008Article
- On evaluating MHC-II binding peptide prediction methods.PloS one · 2008Article
- Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research.BMC immunology · 2008Article
- Hotspot Hunter: a computational system for large-scale screening and selection of candidate immunological hotspots in pathogen proteomes.BMC bioinformatics · 2008Article
- A statistical framework for modeling HLA-dependent T cell response data.PLoS computational biology · 2007Article
- More than one reason to rethink the use of peptides in vaccine design.Nature reviews. Drug discovery · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Experimental approaches for identifying T-cell epitopes are time-consuming, costly and not applicable to the large scale screening. Computer modeling methods can help to minimize the number of experiments required, enable a systematic scanning for candidate major histocompatibility complex (MHC) binding peptides and thus speed up vaccine development. We developed a prediction system based on a novel data representation of peptide/MHC interaction and support vector machines (SVM) for prediction of peptides that promiscuously bind to multiple Human Leukocyte Antigen (HLA, human MHC) alleles belonging to a HLA supertype. Ten-fold cross-validation results showed that the overall performance of SVM models is improved in comparison to our previously published methods based on hidden Markov models (HMM) and artificial neural networks (ANN), also confirmed by blind testing. At specificity 0.90, sensitivity values of SVM models were 0.90 and 0.92 for HLA-A2 and -A3 dataset respectively. Average area under the receiver operating curve (A(ROC)) of SVM models in blind testing are 0.89 and 0.92 for HLA-A2 and -A3 datasets. A(ROC) of HLA-A2 and -A3 SVM models were 0.94 and 0.95, validated using a full overlapping study of 9-mer peptides from human papillomavirus type 16 E6 and E7 proteins. In addition, a large-scale experimental dataset has been used to validate HLA-A2 and -A3 SVM models. The SVM prediction models were integrated into a web-based computational system MULTIPRED1, accessible at antigen.i2r.a-star.edu.sg/multipred1/.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.